Cargando…

Differential infectivity of gametocytes after artemisinin-based combination therapy of uncomplicated falciparum malaria

BACKGROUND: Most malaria-endemic countries use artemisinin-based combination therapy (ACT) as their first-line treatment. ACTs are known to be highly effective on asexual stages of the malaria parasite. Malaria transmission and the spread of resistant parasites depend on the infectivity of gametocyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouologuem, Dinkorma T., Kone, Cheick O., Fofana, Bakary, Sidibe, Bakary, Togo, Amadou H., Dembele, Demba, Toure, Sekou, Koumare, Sekou, Toure, Ousmane, Sagara, Issaka, Toure, Abdoulaye, Dao, Adama, Doumbo, Ogobara K., Djimde, Abdoulaye A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AOSIS 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295776/
https://www.ncbi.nlm.nih.gov/pubmed/30568901
http://dx.doi.org/10.4102/ajlm.v7i2.784
_version_ 1783380925836427264
author Ouologuem, Dinkorma T.
Kone, Cheick O.
Fofana, Bakary
Sidibe, Bakary
Togo, Amadou H.
Dembele, Demba
Toure, Sekou
Koumare, Sekou
Toure, Ousmane
Sagara, Issaka
Toure, Abdoulaye
Dao, Adama
Doumbo, Ogobara K.
Djimde, Abdoulaye A.
author_facet Ouologuem, Dinkorma T.
Kone, Cheick O.
Fofana, Bakary
Sidibe, Bakary
Togo, Amadou H.
Dembele, Demba
Toure, Sekou
Koumare, Sekou
Toure, Ousmane
Sagara, Issaka
Toure, Abdoulaye
Dao, Adama
Doumbo, Ogobara K.
Djimde, Abdoulaye A.
author_sort Ouologuem, Dinkorma T.
collection PubMed
description BACKGROUND: Most malaria-endemic countries use artemisinin-based combination therapy (ACT) as their first-line treatment. ACTs are known to be highly effective on asexual stages of the malaria parasite. Malaria transmission and the spread of resistant parasites depend on the infectivity of gametocytes. The effect of the current ACT regimens on gametocyte infectivity is unclear. OBJECTIVES: This study aimed to determine the infectivity of gametocytes to Anopheles gambiae following ACT treatment in the field. METHODS: During a randomised controlled trial in Bougoula-Hameau, Mali, conducted from July 2005 to July 2007, volunteers with uncomplicated malaria were randomised to receive artemether-lumefantrine, artesunate-amodiaquine, or artesunate-sulfadoxine/pyrimethamine. Volunteers were followed for 28 days, and gametocyte carriage was assessed. Direct skin feeding assays were performed on gametocyte carriers before and after ACT administration. RESULTS: Following artemether-lumefantrine treatment, gametocyte carriage decreased steadily from Day 0 to Day 21 post-treatment initiation. In contrast, for the artesunate-amodiaquine and artesunate-sulfadoxine/pyrimethamine arms, gametocyte carriage increased on Day 3 and remained constant until Day 7 before decreasing afterward. Mosquito feeding assays showed that artemether-lumefantrine and artesunate-amodiaquine significantly increased gametocyte infectivity to Anopheles gambiae sensu lato (s.l.) (p < 10(−4)), whereas artesunate-sulfadoxine/pyrimethamine decreased gametocyte infectivity in this setting (p = 0.03). CONCLUSION: Different ACT regimens could lead to gametocyte populations with different capacity to infect the Anopheles vector. Frequent assessment of the effect of antimalarials on gametocytogenesis and gametocyte infectivity may be required for the full assessment of treatment efficacy, the potential for spread of drug resistance and malaria transmission in the field.
format Online
Article
Text
id pubmed-6295776
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher AOSIS
record_format MEDLINE/PubMed
spelling pubmed-62957762018-12-19 Differential infectivity of gametocytes after artemisinin-based combination therapy of uncomplicated falciparum malaria Ouologuem, Dinkorma T. Kone, Cheick O. Fofana, Bakary Sidibe, Bakary Togo, Amadou H. Dembele, Demba Toure, Sekou Koumare, Sekou Toure, Ousmane Sagara, Issaka Toure, Abdoulaye Dao, Adama Doumbo, Ogobara K. Djimde, Abdoulaye A. Afr J Lab Med Original Research BACKGROUND: Most malaria-endemic countries use artemisinin-based combination therapy (ACT) as their first-line treatment. ACTs are known to be highly effective on asexual stages of the malaria parasite. Malaria transmission and the spread of resistant parasites depend on the infectivity of gametocytes. The effect of the current ACT regimens on gametocyte infectivity is unclear. OBJECTIVES: This study aimed to determine the infectivity of gametocytes to Anopheles gambiae following ACT treatment in the field. METHODS: During a randomised controlled trial in Bougoula-Hameau, Mali, conducted from July 2005 to July 2007, volunteers with uncomplicated malaria were randomised to receive artemether-lumefantrine, artesunate-amodiaquine, or artesunate-sulfadoxine/pyrimethamine. Volunteers were followed for 28 days, and gametocyte carriage was assessed. Direct skin feeding assays were performed on gametocyte carriers before and after ACT administration. RESULTS: Following artemether-lumefantrine treatment, gametocyte carriage decreased steadily from Day 0 to Day 21 post-treatment initiation. In contrast, for the artesunate-amodiaquine and artesunate-sulfadoxine/pyrimethamine arms, gametocyte carriage increased on Day 3 and remained constant until Day 7 before decreasing afterward. Mosquito feeding assays showed that artemether-lumefantrine and artesunate-amodiaquine significantly increased gametocyte infectivity to Anopheles gambiae sensu lato (s.l.) (p < 10(−4)), whereas artesunate-sulfadoxine/pyrimethamine decreased gametocyte infectivity in this setting (p = 0.03). CONCLUSION: Different ACT regimens could lead to gametocyte populations with different capacity to infect the Anopheles vector. Frequent assessment of the effect of antimalarials on gametocytogenesis and gametocyte infectivity may be required for the full assessment of treatment efficacy, the potential for spread of drug resistance and malaria transmission in the field. AOSIS 2018-12-06 /pmc/articles/PMC6295776/ /pubmed/30568901 http://dx.doi.org/10.4102/ajlm.v7i2.784 Text en © 2018. The Authors https://creativecommons.org/licenses/by/4.0/ Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.
spellingShingle Original Research
Ouologuem, Dinkorma T.
Kone, Cheick O.
Fofana, Bakary
Sidibe, Bakary
Togo, Amadou H.
Dembele, Demba
Toure, Sekou
Koumare, Sekou
Toure, Ousmane
Sagara, Issaka
Toure, Abdoulaye
Dao, Adama
Doumbo, Ogobara K.
Djimde, Abdoulaye A.
Differential infectivity of gametocytes after artemisinin-based combination therapy of uncomplicated falciparum malaria
title Differential infectivity of gametocytes after artemisinin-based combination therapy of uncomplicated falciparum malaria
title_full Differential infectivity of gametocytes after artemisinin-based combination therapy of uncomplicated falciparum malaria
title_fullStr Differential infectivity of gametocytes after artemisinin-based combination therapy of uncomplicated falciparum malaria
title_full_unstemmed Differential infectivity of gametocytes after artemisinin-based combination therapy of uncomplicated falciparum malaria
title_short Differential infectivity of gametocytes after artemisinin-based combination therapy of uncomplicated falciparum malaria
title_sort differential infectivity of gametocytes after artemisinin-based combination therapy of uncomplicated falciparum malaria
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295776/
https://www.ncbi.nlm.nih.gov/pubmed/30568901
http://dx.doi.org/10.4102/ajlm.v7i2.784
work_keys_str_mv AT ouologuemdinkormat differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT konecheicko differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT fofanabakary differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT sidibebakary differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT togoamadouh differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT dembeledemba differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT touresekou differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT koumaresekou differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT toureousmane differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT sagaraissaka differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT toureabdoulaye differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT daoadama differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT doumboogobarak differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria
AT djimdeabdoulayea differentialinfectivityofgametocytesafterartemisininbasedcombinationtherapyofuncomplicatedfalciparummalaria